Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cholesterol
Biotech
CRISPR Tx sees 80% fall in LDL, triglycerides after in vivo edit
CRISPR Tx reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310.
Nick Paul Taylor
May 7, 2025 10:00am
Marea rises toward phase 2b after posting cholesterol data
May 7, 2025 8:25am
AZ's oral PCSK9 inhibitor halves bad cholesterol in phase 2
Mar 31, 2025 12:00pm
Repair licenses Genevant's tech for up to $107M per product
Sep 26, 2024 2:53pm
NewAmsterdam drug cuts cholesterol, but by less than expected
Jul 29, 2024 8:00am
Marea ropes in $190M for clinical-stage cardiometabolic program
Jun 18, 2024 7:00am
